Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate (original) (raw)
Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate
Chun-nan Yeh
World journal of gastroenterology : WJG, 2006
View PDFchevron_right
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials
Shreyaskumar Patel
European Journal of Cancer, 2008
View PDFchevron_right
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial
Raija Kallio
JAMA oncology, 2017
View PDFchevron_right
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
George Demetri
Journal of Clinical Oncology, 2003
View PDFchevron_right
Factors Associated With Disease Progression in Patients With Gastrointestinal Stromal Tumors in the Pre-Imatinib Era
Madelon Vonk
American Journal of Clinical Pathology, 2005
View PDFchevron_right
Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor
George Demetri
Annals of Surgery, 2013
View PDFchevron_right
Evaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment
Ivan Damjanov
The Open Pathology Journal, 2009
View PDFchevron_right
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall
Maria Debiec-Rychter
Histopathology, 2005
View PDFchevron_right
Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapy
G.eorges F Samelis
European Journal of Surgical Oncology (EJSO), 2007
View PDFchevron_right
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
George Demetri
New England Journal of Medicine, 2002
View PDFchevron_right
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Raija Kallio
Clinical Cancer Research, 2023
View PDFchevron_right
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
Maria Debiec-Rychter
European Journal of Cancer, 2008
View PDFchevron_right
Systemic therapy in gastrointestinal stromal tumors
Oncology and Translational Medicine
Oncology and Translational Medicine, 2024
View PDFchevron_right
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib
Raija Kallio
JAMA Oncology, 2017
View PDFchevron_right
KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib
Paul Waring
Histopathology, 2006
View PDFchevron_right
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors
Mehrdad Nikfarjam
Gastrointestinal cancer research: GCR
View PDFchevron_right
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
Tommaso Pas
Annals of Oncology, 2007
View PDFchevron_right
Study Protocol from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Raija Kallio
2023
View PDFchevron_right
Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate
Shreyaskumar Patel
Cancer, 2006
View PDFchevron_right
Data from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Raija Kallio
2023
View PDFchevron_right
Gastrointestinal Stromal Tumors: Morphological, Immunohistochemical and Molecular Changes Associated with Kinase Inhibitor Therapy
Mario Delgado
Pathology & Oncology Research, 2011
View PDFchevron_right
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts
Sandra Silberman
European Journal of Cancer, 2002
View PDFchevron_right
Gastrointestinal Stromal Tumors: Case Series of 29 Patients Defining the Role of Imatinib Prior to Surgery
Supreeta Arya
2012
View PDFchevron_right
Gastrointestinal stromal tumour treated with neoadjuvant imatinib
Paul Waring
Journal of Clinical Pathology, 2005
View PDFchevron_right
Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned
chun tsai
Anticancer research, 2014
View PDFchevron_right
Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs)
marco alessandro pierotti
The Journal of Pathology, 2009
View PDFchevron_right
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
Ian Judson, Sandra Silberman
The Lancet, 2001
View PDFchevron_right
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
Sheng-fung Lin, Li-tzong Chen
The Kaohsiung Journal of Medical Sciences, 2006
View PDFchevron_right
Gastrointestinal stromal tumors in the imatinib era: 15 years' experience of a tertiary center
Guilherme Macedo
Journal of gastrointestinal oncology, 2018
View PDFchevron_right
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
Jan Andersson
British journal of cancer, 2003
View PDFchevron_right
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
Daniel Stepan, MD
Cancer Chemotherapy and Pharmacology, 2010
View PDFchevron_right
Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy
JORGE APARICIO
Revista Espanola De Enfermedades Digestivas, 2004
View PDFchevron_right